Stocks Screener

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Dynavax Technologies Corporation

DYF1
Current price
10.88 EUR 0 EUR (0.00%)
Last closed 11.85 USD
ISIN US2681582019
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Exchange Frankfurt Exchange
Capitalization 1 514 892 800 USD
Yield for 12 month -17.16 %
1Y
3Y
5Y
10Y
15Y
DYF1
21.11.2021 - 28.11.2021

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. The company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; Biological E. Limited; PT Bio Farma; Medigen Vaccine Biologics; and Serum Institute of India Pvt. Ltd. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. The company was incorporated in 1996 and is headquartered in Emeryville, California. Address: 2100 Powell Street, EmeryVille, CA, United States, 94608

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

24.5 USD

P/E ratio

87.6154

Dividend Yield

Current Year

+232 284 000 USD

Last Year

+722 683 000 USD

Current Quarter

+73 795 000 USD

Last Quarter

+50 790 000 USD

Current Year

+182 117 000 USD

Last Year

+460 530 000 USD

Current Quarter

+61 810 000 USD

Last Quarter

+39 824 000 USD

Key Figures DYF1

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -7 871 000 USD
Operating Margin TTM 10.03 %
PE Ratio 87.6154
Return On Assets TTM -0.79 %
PEG Ratio
Return On Equity TTM 2.82 %
Wall Street Target Price 24.5 USD
Revenue TTM 249 694 000 USD
Book Value 4.91 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 22.5 %
Dividend Yield
Gross Profit TTM 448 218 000 USD
Earnings per share 0.13 USD
Diluted Eps TTM 0.13 USD
Most Recent Quarter II 2024
Quarterly Earnings Growth YOY 207.2 %
Profit Margin 6.88 %

Dividend Analytics DYF1

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History DYF1

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor 1:10
Payout Ratio
Last Split Date 10.11.2014
Dividend Date

Stock Valuation DYF1

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE 87.6154
Forward PE 53.4759
Enterprise Value Revenue 3.679
Price Sales TTM 6.067
Enterprise Value EBITDA 27.7847
Price Book MRQ 2.1832

Financials DYF1

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators DYF1

For 52 weeks

9.74 USD 15.15 USD
50 Day MA 11.02 USD
Shares Short Prior Month 17 043 685
200 Day MA 11.7 USD
Short Ratio 10.53
Shares Short 17 059 789
Short Percent 15.91 %